drugset / Trial / NCT02516696
BiRd vs. Rd as Initial Therapy in Multiple Myeloma
Phase 3
Terminated
12 enrolled
Weill Medical College of Cornell University
Celgene Corporation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®), in multiple myeloma patients who are newly diagnosed and require treatment when compared to patients who receive lenalidomide and dexamethasone alone.
Timeline
- Start
- 2016-02
- Primary completion
- 2022-06-22
- Completion
- 2022-07-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 500 mg | Oral |
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |